Janus Henderson Group
TSHA icon

Janus Henderson Group’s Taysha Gene Therapies TSHA Stock Holding History

Janus Henderson Group’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$308K Hold
69,000
– – ﹤0.01% 2207
2025
Q4 		$378K Buy
+69,000
New +$335K ﹤0.01% 2127

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Janus Henderson Group's TSHA Position: Q1 2026 in Review

Janus Henderson Group held its Taysha Gene Therapies (TSHA) position steady in Q1 2026 at 69,000 shares worth $308K. The position accounts for ﹤0.01% of the portfolio, ranked #2207.

Janus Henderson Group first reported a position in TSHA in Q4 2025 and has held it in 2 quarters since. The position peaked at $378K in Q4 2025. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

  • Janus Henderson Group held 69,000 shares of Taysha Gene Therapies worth $308K as of Q1 2026.
  • Janus Henderson Group left its Taysha Gene Therapies share count unchanged in Q1 2026.
  • Taysha Gene Therapies made up ﹤0.01% of Janus Henderson Group's portfolio in Q1 2026, its #2207 holding.
  • Janus Henderson Group first reported a position in Taysha Gene Therapies in Q4 2025 and has held it in 2 quarters since.
  • Janus Henderson Group's Taysha Gene Therapies position peaked at $378K in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.